ACRO Biomedical Wins National Innovation Award for the Third Time

ACRO Biomedical (Stock Code: 6748), a leading innovator in human organ and tissue regeneration and biomedical materials, has once again gained recognition from the international biotech community.

• In 2017, ACRO won the 14th National Innovation Award for its Artificial Corneal Stroma technology.

• In 2021, it secured the 18th National Innovation Award for its Innovative Organ Regeneration Technology.

• Now, in 2024, ACRO has been awarded the 21st National Innovation Award for the Innovative Application of Acellular Dermal Matrix (Micro-Particle) in Medical Devices.

This third prestigious recognition reaffirms that regenerative therapy is no longer just a concept—it is becoming a reality.

Breakthroughs in Regenerative Medical Devices

ACRO Biomedical has been winning industry accolades over the past two years. In 2023, it received:

• The Taiwan BIO Awards for industrial innovation.

• The Pharmaceutical Technology & Research Development Award - Silver Award for its advanced manufacturing technology.

In April 2024, ACRO took another major step by securing Class III medical device approvals from Taiwan’s Ministry of Health and Welfare (TFDA) for three regenerative medical products:

• Collagen Hemostatic Matrix

• Hemostatic ADM Scaffold

• Hemostatic ADM Paste

By December 2024, ACRO was again honored with the 21st National Innovation Award for its Innovative Application of Acellular Dermal Scaffold in Medical Devices.

ACRO continues to accelerate product development, clinical validation, and regulatory approvals, aiming to deliver high-quality and affordable medical solutions to patients. At the same time, this achievement signals to the industry that regenerative medicine is an essential pillar of the future healthcare landscape.

Leading the Future of Regenerative Medicine

Dr. Dar-Jen Hsieh, Chairman of ACRO Biomedical, emphasized that regenerative medicine is a rapidly growing global industry that requires continuous investment in R&D and clinical trials in collaboration with leading domestic and international medical institutions.

All ACRO Biomedical products undergo rigorous regulatory evaluations and comply with TFDA’s stringent approval standards, ensuring safety and reliability for medical professionals and patients alike.

Dr. Hsieh also highlighted the prestige of the National Innovation Award, describing it as "the Oscars of the biomedical industry." Winning the 21st National Innovation Award / Corporate Innovation Award demonstrates ACRO’s commitment to advancing human organ and tissue regeneration, a field that is gaining increasing recognition in biomedical applications worldwide.

We continue to make the impossible POSSIBLE.

URL:ACRO Biomedical Wins National Innovation Award for the Third Time